Comparison of the two most commonly used treatments for pyoderma gangrenosum: results of the STOP GAP randomised controlled trial by Ormerod, Anthony D. et al.
RESEARCH
1the bmj | BMJ 2015;350:h2958 | doi: 10.1136/bmj.h2958
1Division of Applied Medicine, 
Aberdeen University, Aberdeen, 
UK
2Centre of Evidence Based 
Dermatology, University of 
Nottingham, NG7 2NR, UK
3Department of Dermatology, 
Aberdeen Royal Infirmary, 
Aberdeen, UK
4Nottingham Clinical Trials Unit, 
University of Nottingham, 
Nottingham, UK
5Robertson Centre for 
Biostatistics, University of 
Glasgow, Glasgow, UK
6Centre for Healthcare 
Randomised Trials, Aberdeen 
University, Aberdeen, UK
7School of Medicine, Pharmacy 
and Health, Durham University, 
Durham, UK
8Department of Dermatology, 
Hull Royal Infirmary, Hull, UK
9Department of Dermatology, 
Leicester Royal Infirmary, 
Leicester, UK
Correspondence to: 
K S Thomas  
kim.thomas@ nottingham.ac.uk
Additional material is published 
online only. To view please visit 
the journal online (http://dx.doi.
org/10.1136/bmj.h2958)
Cite this as: BMJ 2015;350:h2958
doi: 10.1136/bmj.h2958
Accepted: 27 April 2015
Comparison of the two most commonly used treatments for 
pyoderma gangrenosum: results of the STOP GAP randomised 
controlled trial
Anthony D Ormerod,1 Kim S Thomas,2 Fiona E Craig,3 Eleanor Mitchell,4 Nicola Greenlaw,5 
John Norrie,6 James M Mason,7 Shernaz Walton,8 Graham A Johnston,9 Hywel C Williams2 
on behalf of the UK Dermatology Clinical Trials Network’s STOP GAP team
ABSTRACT
ObjeCtive
To determine whether ciclosporin is superior to 
prednisolone for the treatment of pyoderma 
gangrenosum, a painful, ulcerating skin disease with a 
poor evidence base for management.
Design 
Multicentre, parallel group, observer blind, 
randomised controlled trial. 
setting
39 UK hospitals, recruiting from June 2009 to 
November 2012.
PartiCiPants
121 patients (73 women, mean age 54 years) with 
clinician diagnosed pyoderma gangrenosum. Clinical 
diagnosis was revised in nine participants after 
randomisation, leaving 112 participants in the analysis 
set (59 ciclosporin; 53 prednisolone).
interventiOn
Oral prednisolone 0.75 mg/kg/day compared with 
ciclosporin 4 mg/kg/day, to a maximum dose of 75 and 
400 mg/day, respectively.
Main OutCOMe Measures
The primary outcome was speed of healing over six 
weeks, captured using digital images and assessed by 
blinded investigators. Secondary outcomes were time 
to healing, global treatment response, resolution of 
inflammation, self reported pain, quality of life, 
number of treatment failures, adverse reactions, and 
time to recurrence. Outcomes were assessed at 
baseline and six weeks and when the ulcer had healed 
(to a maximum of six months).
results
Of the 112 participants, 108 had complete primary 
outcome data at baseline and six weeks (57 
ciclosporin; 51 prednisolone). Groups were balanced at 
baseline. The mean (SD) speed of healing at six weeks 
was −0.21 (1.00) cm2/day in the ciclosporin group 
compared with −0.14 (0.42) cm2/day in the 
prednisolone group. The adjusted mean difference 
showed no between group difference (0.003 cm2/day, 
95% confidence interval −0.20 to 0.21; P=0.97). By six 
months, ulcers had healed in 28/59 (47%) participants 
in the ciclosporin group compared with 25/53 (47%) in 
the prednisolone group. In those with healed ulcers, 
eight (30%) receiving ciclosporin and seven (28%) 
receiving prednisolone had a recurrence. Adverse 
reactions were similar for the two groups (68% 
ciclosporin and 66% prednisolone), but serious 
adverse reactions, especially infections, were more 
common in the prednisolone group.
COnClusiOn
Prednisolone and ciclosporin did not differ across a 
range of objective and patient reported outcomes. 
Treatment decisions for individual patients may be 
guided by the different side effect profiles of the two 
drugs and patient preference. 
trial registratiOn
Current Controlled Trials ISRCTN35898459.
Introduction
Pyoderma gangrenosum is a rare inflammatory disor-
der that causes progressive necrotising ulceration. A 
retrospective cohort study of UK cases reported an age 
and sex adjusted incidence of 0.63 per 100 000 person 
years.1  Several variants of pyoderma gangrenosum 
have been recognised, but the classic form of the dis-
ease is the most commonly encountered.2  Manifesta-
tions of pyoderma gangrenosum are predominantly 
cutaneous, typically beginning as a tender erythema-
tous nodule or pustule that rapidly breaks down to 
form a large, well demarcated ulcer with purplish, 
undermined edges. The condition is often observed in 
patients with an underlying systemic disease and has 
been particularly associated with inflammatory bowel 
disease, arthritis, and haematological malignancies.3 
Approximately 25% of cases are precipitated by inci-
dental or iatrogenic trauma, a phenomenon known as 
pathergy.4-7 The development of pyoderma gangreno-
sum is associated with a threefold increased risk of 
WhAT IS AlReAdy knoWn on ThIS TopIC
Pyoderma gangrenosum is a severe, painful ulcerative skin condition that has a 
weak evidence base for treatments, with only one published randomised controlled 
trial of 30 participants
Prednisolone has been the main systemic treatment, but many clinicians now use 
ciclosporin in the belief that it is more effective and has fewer side effects
Both prednisolone and ciclosporin have important, predictable side effects
WhAT ThIS STudy AddS
In this pragmatic randomised controlled trial, ciclosporin and prednisolone were of 
similar efficacy, but only 50% of ulcers had healed by six months, 
Adverse events were common, occurring in around two thirds of participants taking 
either study drug suggesting that better treatments are required
The adverse event profile (serious infections with prednisolone, hypertension and 
renal dysfunction with ciclosporin) may help to inform decisions about treatment 
depending on underlying comorbidities
 open access
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death (hazard ratio 3.03) compared with that of con-
trols from the general population, and a 72% increased 
mortality over controls with inflammatory bowel 
 disease.1 
Currently there are no national or international 
guidelines covering the management of pyoderma gan-
grenosum. Patient information issued by the British 
Association of Dermatologists describes topical and 
systemic treatment options, as well as lesser used 
options such as intravenous steroids or biologics.8  The 
most commonly prescribed topical treatments for pyo-
derma gangrenosum are potent steroid preparations 
and calcineurin inhibitors, and commonly prescribed 
systemic treatments include steroids and immunosup-
pressants.8
Only one randomised controlled trial in patients with 
pyoderma gangrenosum is reported in the literature.9 
This small, placebo controlled study of 30 patients 
assessed infliximab, which is not considered to be a first 
line treatment for pyoderma gangrenosum. There is a 
complete lack of studies assessing the efficacy of com-
monly used treatments for pyoderma gangrenosum, so 
systematic reviews have primarily relied on anecdotal 
reports or retrospective case series.10 Given the com-
plete absence of high quality evidence on treatments, 
we carried out a randomised controlled trial (STOP GAP, 
Study of Treatments fOr Pyoderma GAngrenosum 
Patients) to test the hypothesis that ciclosporin is supe-
rior to prednisolone in the treatment of pyoderma gan-
grenosum.
Methods
The trial protocol has been published previously.11
trial design and oversight
We carried out a multicentre, parallel group, observer 
blind randomised controlled trial to compare the effi-
cacy and safety of ciclosporin with that of prednisolone. 
Participants gave written informed consent. Oversight 
of the trial included a trial management group and 
independent trial steering and data monitoring com-
mittees. Patients suitable for topical treatment were 
entered into a parallel observational study, the results 
of which will be reported separately.
Patient involvement
Patients were involved in the design and conduct of this 
research. During the feasibility stage, priority of the 
research question, choice of outcome measures, and 
methods of recruitment were informed by discussions 
with patients through a focus group session and two 
structured interviews. During the trial, a patient joined 
the independent trial steering committee. Members of 
the UK Dermatology Clinical Trials Network also identi-
fied this research as being a priority area for clinicians 
treating patients with pyoderma gangrenosum. Once 
the trial has been published, participants will be 
informed of the results through a dedicated website 
(www.stopgaptrial.co.uk) and will be sent details of 
the  results in a study newsletter suitable for a non- 
specialist audience.
Participants
Recruitment took place at 39 hospitals in the United 
Kingdom. Participants were aged 18 years or more, with 
a diagnosis of pyoderma gangrenosum made by a 
recruiting dermatologist. Histopathology is rarely 
pathognomonic for pyoderma gangrenosum, and many 
clinicians avoid biopsy because of the risk of an immu-
nological reaction that results in ulcer extension at the 
biopsy site. If the clinical diagnosis was uncertain, a 
biopsy was performed to exclude other diagnoses such 
as malignancy, granulomatous pyoderma gangreno-
sum, and arteritis, and advice was sought from an expert 
panel as necessary.
We excluded patients with pustular or granulomatous 
variants of pyoderma gangrenosum (as they may 
respond differently to treatment, and measurement of a 
single ulcer was not possible); patients receiving oral 
prednisolone, ciclosporin, or intravenous immunoglob-
ulin in the previous month; patients participating in 
another clinical trial; women who were pregnant, lactat-
ing, or at risk of pregnancy; patients with known hyper-
sensitivity to either of the study treatments; patients 
with clinically important renal impairment or other pre-
treatment findings that would result in the investigator 
not using either of the study drugs; patients with malig-
nant or premalignant disease; patients with a concur-
rent medical condition for which treatments might 
interfere with ongoing treatment or cause harm; and 
patients taking rosuvastatin or those who had received a 
live vaccine in the two weeks before randomisation.
interventions
Participants received oral prednisolone (brand chosen 
according to local practice) 0.75 mg/kg/day in a single 
dose or ciclosporin (Neoral; Novartis) 4 mg/kg/day in 
two divided doses. As this was a pragmatic trial, the 
dose could be adjusted according to normal practice, to 
a maximum of 1 mg/kg/day for prednisolone and 5 mg/
kg/day for ciclosporin.7 10 Topical treatment was prohib-
ited during the trial. A change to the protocol was made 
in August 2011 (after 82 participants had been enrolled) 
as bowel perforation was experienced by a participant 
receiving prednisolone 110 mg/day. As a result we 
implemented ceiling doses of 75 mg/day for predniso-
lone and 400 mg/day for ciclosporin.
randomisation and blinding
Participants were randomised (1:1) to treatment alloca-
tion using a web based randomisation system hosted by 
Nottingham Clinical Trials Unit, using a computer gen-
erated pseudorandom list, with permuted blocks of 
randomly varying size between two and six (RALLOC 
add-on12 for Stata, TX). Randomisation was stratified by 
target lesion size (<20 cm2; ≥20 cm2) and presence or 
absence of underlying systemic disease. It was not pos-
sible to blind clinicians and participants to treatment 
allocation owing to resource limitations and the com-
plexities of different dosing regimens and safety testing 
of the two drugs. As a result, clinicians and participants 
were informed of their treatment allocation once data 
had been irrevocably entered into the randomisation 
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database. Treatment allocation was concealed from the 
statistician and blinded assessors of the digital images 
until interventions were all assigned and recruitment, 
data collection, data cleaning, and blind analysis were 
complete.
Assessors blind to the allocated treatment assessed 
the ulcer size and global treatment response from digi-
tal images of the target lesion. If digital images were not 
available, the assessors used physical measurements of 
the lesion taken during clinic visits and global response 
by the treating clinician.
assessments
Clinic visits took place at baseline, week 2, and week 6 
(primary outcome) and when the ulcer had healed (up 
to a maximum of six months). Patient reported out-
comes were collected from daily diaries or postal ques-
tionnaires. For participants whose pyoderma 
gangrenosum had healed, we assessed recurrence and 
time to recurrence from medical notes.
Digital image assessments
A template was photographed alongside the target 
ulcer to calibrate the image in the image analysis soft-
ware (see supplementary figure). Two trained assessors 
mapped the circumference of the lesion using VERG 
Videometry VEV MD software (Vista Medical, Winni-
peg, Canada). Two dermatologists independently 
reviewed all images to ensure that the lesions were con-
sistent with a diagnosis of pyoderma gangrenosum and 
that the measurements taken by the trained assessors 
were an accurate representation of the ulcer’s size.
Outcomes
Primary outcome
The main outcome measure was speed of healing over 
six weeks, captured for a single target lesion for each 
patient. If multiple lesions were present, we designated 
the largest lesion that could be photographed on a sin-
gle plane as the target lesion.
We chose speed of healing for the primary outcome 
as previous studies have shown it to be a good predictor 
of healing in patients with leg ulcers,13 14 and because 
blinded outcome assessment was possible using digital 
images and independent assessors. Assessing the pri-
mary outcome at six weeks also minimised loss to fol-
low-up and the impact of participants switching to 
alternative treatments before primary outcome assess-
ment. In cases where digital images were unavailable, 
or of poor quality, we used physical measurements of 
the ulcer taken by non-blinded clinicians at baseline 
and six weeks.
secondary outcomes
Time to healing—defined as the time at which sterile 
dressings were no longer required (reported by patients 
and confirmed by clinicians at subsequent clinic visits). 
We identified this outcome as the most important of the 
secondary outcomes.
Pyoderma gangrenosum specific global treatment 
response—to assess treatment response we used a seven 
point Likert scale ranging from completely clear 
through to worse (assessed by clinicians and partici-
pants and from digital images for blinded assessment).
Resolution of inflammation—this was recorded by cli-
nicians and participants using a scale reported by 
Foss.15
Self reported pain—participants self reported the 
severity of pain daily using a score from 0 to 4 (none, 
mild, moderate, severe, or extreme).
Health related quality of life—assessed using the 
dermatology life quality index16  and European quality 
of life-5 dimensions, three levels (EQ-5D-3L and EQ 
VAS).17 18
Time to recurrence—defined as the interval between 
the target lesion healing and a further episode of pyo-
derma gangrenosum (at any site). The period of fol-
low-up available varied depending on the time at which 
participants were randomised into the trial.
Number of treatment failures—defined as those who 
withdrew from their randomised treatment because of 
treatment intolerance, whose pyoderma gangrenosum 
worsened, or whose target lesion remained unhealed 
after six months of follow-up.
Adverse reactions to study drugs—adverse events that 
were possibly, probably, or definitely related to the 
study drug.
sample size
This was a superiority trial, with prednisolone as the 
control intervention. To provide 80% power (5% level of 
significance) to detect a difference in means of 0.5 stan-
dard deviations in the primary outcome of speed of 
healing over six weeks, the target sample size was 140 
participants, assuming a loss to follow-up of 10%. We 
chose a difference of 0.5 standard deviations as being a 
clinically meaningful between group difference, as 
observational data suggested that ciclosporin was 
potentially more effective, but at higher cost, than pred-
nisolone.19-21 As a result, we felt that a substantial treat-
ment effect was necessary to justify a change in clinical 
practice.
statistical analysis
We prespecified all analyses in a statistical analysis 
plan. Analysis was conducted using intention to treat 
principles; defined as all randomised participants, 
excluding those with a later diagnosis determined to be 
something other than pyoderma gangrenosum. We 
included all participants with available data at both the 
baseline and the six week visit in the primary analysis. 
The impact of missing values was explored in sensitiv-
ity analysis. A linear regression model was used to anal-
yse differences between treatment groups for the 
primary outcome at six weeks, adjusting for the stratifi-
cation variables.
Secondary outcomes were analysed using Cox regres-
sion models (for time to event outcomes); linear regres-
sion models for dermatology life quality index, EQ-5D, 
and EQ-VAS (adjusted for baseline values), and for self 
reported pain (which were summarised using area 
under the curve); proportional odds models for ordered 
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categorical outcomes; and logistic regression models 
for binary outcomes. All analyses were adjusted for the 
stratification variables.
Sensitivity analysis of the primary outcome and time 
to healing were further adjusted for additional baseline 
variables including age, sex, weight, size of recruiting 
centre and geographical region; missing data; and par-
ticipants who switched randomised treatments or 
received the trial drugs in combination during the 
period of the trial. 
We analysed adverse reactions that occurred during 
the trial according to the original randomised alloca-
tion, regardless of whether other drugs had been intro-
duced before the adverse reaction.
All statistical analyses were conducted using SAS 
software, version 9.2 and R version 2.10.1.
Results
Of 499 patients screened from June 2009 to November 
2012, 121 were eligible and gave written informed con-
sent (86% of target of 140 participants) (fig 1).
Table 1 summarises the baseline characteristics of the 
participants. Nine were excluded after randomisation 
because histological findings failed to support a diag-
nosis of pyoderma gangrenosum. Such participants 
were randomised before confirmation of biopsy results 
as it was considered unethical to delay treatment for 
those with painful and rapidly spreading ulcers. As 
such, the intention to treat population was 112 partici-
pants (59 ciclosporin; 53 prednisolone). Baseline 
 characteristics were balanced between the groups 
(table 1). Thirteen of the participants had previously 
been enrolled in the observational study of topical 
treatments but had failed to respond to treatment and 
so were subsequently re-consented for the randomised 
controlled trial.
During the trial, 16/112 (14%) participants switched to 
the alternative trial drug and a further eight (7%) 
received the two drugs together. Change in treatment 
occurred before the six week primary outcome assess-
ment in five participants (prednisolone n=1, ciclosporin 
n=4).
Nine participants (8%) increased their dose of ran-
domised drug during the trial: four in the prednisolone 
group, with increases ranging from 0.067 mg/kg daily to 
0.6 mg/kg daily; and five in the ciclosporin group, with 
increases ranging from 0.36 mg/kg daily to 0.98 mg/kg 
daily.
Data on adherence to study drugs from daily diaries 
were available for 68/112 (61%) participants. Of these, 
36/37 (97%) in the ciclosporin group and 29/31 (94%) in 
the prednisolone group took their treatment every day 
throughout the first six weeks of the trial.
Primary outcome
Of the 108 participants with data at baseline and six 
weeks, 86 (80%) had blinded outcome data based on 
digital images. For the other 22 (20%) participants 
whose digital images were either unavailable or of 
insufficient quality to allow assessment, healing speed 
was assessed using unblinded physical measurements 
taken during clinic visits.
There was no between group difference in speed of 
healing over six weeks (adjusted mean difference 0.003 
cm2/day, 95% confidence interval −0.20 to 0.21; P=0.97) 
(table 2). Similar results were observed for sensitivity 
analyses in which missing data were imputed (0.001 
cm2/day, −0.20 to 0.21; P=0.99), and separately, after 
adjusting for additional baseline covariates (−0.10 cm2/
day, −0.33 to 0.13; P=0.38). Excluding the five patients 
who either swapped to the alternative trial drug or used 
both drugs in combination before the six week visit, did 
not change the overall treatment effect (−0.036, −0.21 to 
0.14; P=0.68).
Additional post hoc analysis of data at week 2 showed 
no differences between the groups in onset of treatment 
response (P=0.21). For 33 participants (14 in the 
 prednisolone group; 19 in the ciclosporin group) the 
pyoderma gangrenosum worsened (increased in size) 
between baseline and week 2. The increases varied 
between patients, with a median increase in those that 
increased of 2.16 cm2 in the ciclosporin group and 2.55 
cm2 in the prednisolone group.
For 64 participants (32 in each group) the pyoderma 
gangrenosum improved (decreased in size), with a 
median decrease of those that decreased of 1.96 cm2 in 
the ciclosporin group and 3.04 cm2 in the prednisolone 
group.
Nine participants (four in the prednisolone group; 
five in the ciclosporin group) showed no change in 
lesion area two weeks after baseline, and two had miss-
ing data at week 2.
Ciclosporin group
With data at baseline (n=59)
  Did not receive allocated intervention (n=0)
  Switched to alternative trial drug (n=4)
Prednisolone group
With data at baseline (n=53)
  Did not receive allocated intervention (n=0)
  Switched to alternative trial drug (n=1)
Primary outcome analysis set at 6 weeks (n=51)
Sensitivity analysis imputing missing values
  (n=53)
Assessed for eligibility (n=499)
Randomised (n=121)
Lost to follow-up (n=2):
  Death (n=1)
  Lost to follow-up (n=1)
  Discontinued intervention (n=0)
Withdrawn as subsequent diagnosis not pyoderma gangrenosum (n=9)
Primary outcome analysis set at 6 weeks (n=57)
Sensitivity analysis imputing missing values
  (n=59)
Final visit, up to 6 months (n=59)* Final visit, up to 6 months (n=53)*
Lost to follow-up (n=2):
  Withdrew consent (n=2)
  Discontinued intervention (n=0)
Excluded (n=378):
  Not meeting inclusion criteria (n=228):
    Already taking trial drugs (n=122)
    Other (n=106)
  Declined to participate (n=47)
  Other reasons investigator considered unsuitable (n=36)
  Enrolled into parallel observational study (n=67)
Fig 1 | Flow of participants through study. *number of patients with information on healing 
of lesion at any point up to six months after randomisation (main secondary outcome of 
time to healing)
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secondary outcomes
Time to healing
At six weeks, ulcers had healed in nine (15%) partici-
pants in the ciclosporin group and 11 (21%) in the pred-
nisolone group. By six months, ulcers had healed in 
28/59 (47%) participants in the ciclosporin group and 
25/53 (47%) in the prednisolone group.
The Cox regression model for time to healing showed 
no significant difference between the interventions 
(hazard ratio 0.94, 95% confidence interval 0.55 to 1.63; 
P=0.84) (table 3  and fig 2). Sensitivity analyses adjust-
ing for additional baseline covariates was consistent 
with the main result (hazard ratio 1.01, 95% confidence 
interval 0.57 to 1.79; P=0.98), as was censoring the 16 
participants who changed their treatment (hazard ratio 
0.86, 95% confidence interval 0.49 to 1.52; P=0.60).
Secondary outcomes did not differ significantly 
between the treatment groups, including global assess-
ments of efficacy (fig 3 ), resolution of inflammation 
(tables 4  and 5 ), self reported pain in the first six weeks, 
quality of life over the duration of the study (table 6), 
health related quality of life (table 6), and time to recur-
rence (table 3). Treatment failure was documented in 
29/59 (49%) participants in the ciclosporin group and 
26/53 (49%) in the prednisolone group (P=0.88).
Adverse reactions
Overall, 40 (68%) participants in the ciclosporin group 
and 35 (66%) in the prednisolone group experienced at 
least one adverse reaction. Table 7 presents the specific 
events that occurred in at least 3% of patients in either 
treatment group.
Adverse reactions differed between the treatments in 
line with known side effects of each drug. Notable dif-
ferences included new onset diabetes and hyperglycae-
mia in the prednisolone group, and headaches, 
gastrointestinal disturbance, and renal dysfunction 
commonly in the ciclosporin group.
Nine serious adverse reactions occurred: two in the 
ciclosporin group (ruptured abdominal aortic aneu-
rysm and acute kidney injury with increased serum cre-
atinine (212 µmol/L) levels) and seven in the 
prednisolone group (a bowel perforation; five serious 
infections (one resulted in death) that required admis-
table 1 | baseline characteristics of participants. values are numbers (percentages) 
unless stated otherwise
Characteristics Ciclosporin (n=59) Prednisolone (n=53)
Mean (SD) age (years) 57.2 (16.9) 51.3 (15.2)
Women 42 (71) 31 (58)
White ethnicity 55 (93) 53 (100)
Mean (SD) weight (kg), (range) 88.4 (24.5), (50.0-171.0) 93.2 (27.2), (50.6-151.0)
Underlying comorbidities:
 Crohn’s disease 5 (8) 3 (6)
 Ulcerative colitis 7 (12) 8 (15)
 Rheumatoid arthritis 4 (7) 4 (7)
 Other inflammatory arthritis 3 (5) 3 (6)
 Monoclonal gammopathy 0 (0) 0 (0)
 Myeloma 0 (0) 0 (0)
 Other malignancy 4 (7) 0 (0)
 Diabetes 4 (7) 9 (17)
 Mild renal impairment 2 (3) 0 (0)
 Epilepsy 0 (0) 1 (2)
Characteristics of pyoderma gangrenosum
Type of pyoderma gangrenosum:
 Classic 50 (85) 47 (89)
 Cribriform 4 (7) 2 (4)
 Peristomal 2 (3) 2 (4)
 Bullous 0 (0) 1 (2)
 Unsure 3 (5) 1 (2)
Previous episode of pyoderma gangrenosum 17 (28) 14 (26)
Median area of target lesion (cm2), 
(interquartile range)
9.1, (3.6-24.7) 8.1, (2.4-20.2)
Location of lesion:
 Arm 2 (3) 1 (2)
 Leg 41 (69) 34 (64)
 Other 16 (27) 18 (34)
Mean (SD) No of lesions, (range) 2.2 (1.8), (1-10) 2.6 (2.4),* (1-12)
*Two participants had missing data.
table 2 | speed of healing over six weeks (primary outcome)
treatment 
group
no in 
group
Mean (sD) speed of 
healing (cm2/day)
Mean difference 
(ciclosporin−
prednisolone)
adjusted mean 
difference* (95% Ci) P value
Ciclosporin 57 −0.21 (1.00)
−0.074 0.003 (−0.20 to 0.21) 0.97
Prednisolone 51 −0.14 (0.42)
*Adjusted for stratification variables lesion size and presence of underlying disease. Imputation of missing 
values (n=4) did not alter this result (see main text).
table 3 | time to healing by six months and time to recurrence subsequent to initial healing (secondary outcomes)
treatment group
time to healing recurrence
no in 
group
no (%) 
healed* by 
6 months
Median (iQr) 
time (days)
adjusted hazard 
ratio* (95% Ci) P value
no in 
group
no (%) with 
recurrence†
Median (iQr) 
time to 
recurrence (days)
adjusted hazard 
ratio* (95% Ci) P value
Ciclosporin 59 28 (47) 134 (60-183)
0.94 (0.55 to 1.63) 0.84
27 8 (29.6)
582 (172-932) 1.43 (0.50 to 4.07) 0.50
Prednisolone 53 25 (47) 112 (46-182) 25 7 (28.0) 612 (148-934)
IQR=interquartile range.
*Defined as date dressings were no longer required, or, if this was missing (n=3), date of clinic visit at which healing was confirmed.
†In those with healed ulcers by six months.
Days since randomisation
Pe
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d
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Prednisolone Ciclosporin
Fig 2 | Kaplan Meier plot showing time to healing of ulcer 
by treatment group
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sion to hospital or parenteral antibiotics; and one other 
infection).
discussion
In this pragmatic randomised controlled trial, no differ-
ence was found between the two most commonly used 
treatments for pyoderma gangrenosum, ciclosporin and 
prednisolone, across a range of outcome measures. Con-
trary to the anecdotally derived belief that these drugs 
are efficacious in pyoderma gangrenosum, we found 
that fewer than half of the ulcers healed, even after 
 prolonged treatment, and the speed of onset of response 
did not differ between the two treatments. Approxi-
mately two thirds of participants reported adverse reac-
tions; 12% of whom experienced a serious event. The 
side effects observed were in line with the known side 
effect profiles of these drugs. More serious adverse reac-
tions, especially serious infections, were reported in the 
prednisolone group, although patients receiving ciclo-
sporin were at increased risk of renal toxicity.
A recent expert consensus paper considering safety, 
efficacy, and cost placed prednisolone as preferred 
treatment and ciclosporin as second ranked treatment 
among the many suggested interventions for pyoderma 
gangrenosum.7  None the less, previous studies have 
reported large proportions of people with pyoderma 
gangrenosum achieving complete response with ciclo-
sporin,19-23 which led the current researchers of the 
STOP GAP (Study of Treatments fOr Pyoderma GAngre-
nosum Patients) randomised  controlled trial to test the 
hypothesis that ciclosporin was superior to predniso-
lone for the treatment of  pyoderma gangrenosum.
Healing responses at six weeks in our study were 
broadly similar to those observed for the randomised 
controlled trial of infliximab compared with placebo.9  In 
the STOP GAP trial, ulcers had healed at six weeks in 15% 
of participants in the ciclosporin group and 21% in the 
prednisolone group. By comparison, ulcers had healed 
at six weeks in 21% of participants in the infliximab trial 
(all participants who had not responded to treatment at 
week 2 were offered infliximab regardless of the ran-
domised allocation to infliximab or placebo).9  Subse-
quent observational studies suggest that treatment with 
antitumour necrosis factor is potentially more effective in 
patients with inflammatory bowel disease,24  25 but we did 
not have the power to look at this in the current trial. 
Head to head comparisons of antitumour necrosis factor 
with ciclosporin or prednisolone are needed, along with 
investigation of topical interventions that may provide a 
better risk-benefit profile for patients.
This trial is four times larger than the only other ran-
domised controlled trial conducted in pyoderma gan-
grenosum, and it required national collaboration 
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Fig 3 | global treatment response by clinician, patient, and 
independent clinician from digital images
table 4 | resolution of inflammation at six weeks and by final visit 
treatment group* no in group
no (%) with 
resolution Odds ratio† (95% Ci) P value
Week 6:
 Ciclosporin 56 5 (9)
1.03 (0.27 to 3.97) 0.96
 Prednisolone 51 6 (12)
Final visit‡:
 Ciclosporin 57 10 (18)
1.11 (0.39 to 3.12) 0.85
 Prednisolone 51 10 (20)
*Based on border elevation and erythema reduced to “none.”
†Adjusted for stratification variables (lesion size and presence of underlying disease).
‡Up to six months.
table 5 | Characteristics of changes in target lesions 
(erythema, border elevation, and exudate) as assessed 
by investigator at final visit
assessment of 
target lesions
no (%) in 
ciclosporin group 
(n=57)
no (%) in 
prednisolone group 
(n=51)
Erythema:
 Worse 6 (11) 3 (6)
 Same 11 (19) 10 (20)
 Improved 40 (70) 38 (75)
Border elevation:
 Worse 2 (4) 8 (16)
 Same 15 (26) 9 (18)
 Improved 40 (70) 34 (67)
Exudate:
 Worse 5 (9) 4 (8)
 Same 7 (12) 8 (16)
 Improved 45 (79) 39 (76)
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through the UK Dermatology Clinical Trials Network.26 
Patient recruitment from 39 UK hospitals ensured rep-
resentative sampling; the protocol reflected normal 
clinical practice, with dosing adjusted according to 
clinical need; and outcomes included clinician 
assessed, patient assessed, and independent assess-
ment of digital images.
Every effort was made to capture the primary out-
come in a blinded fashion, and all secondary analyses 
were supportive of this main analysis, although power 
to explore the impact on quality of life was limited 
owing to missing data from postal questionnaires.
Given the lack of a placebo or no treatment third arm 
in this study, it is possible that neither drug is effective 
in treating pyoderma gangrenosum. However, it was 
considered unethical to leave patients with a serious, 
potentially fatal disease, without treatment.
The obtained sample size was slightly smaller than 
had been planned, but the narrow confidence intervals 
for between group comparisons suggest that we did not 
miss clinically important differences. The trial was 
stopped after achieving 86% of target recruitment owing 
to time and financial limitations. This decision was made 
before the database was locked and data analysed.
Conclusion
Patients who require systemic treatment are likely to 
respond similarly to prednisolone or ciclosporin in the 
short term, but neither treatment is especially effective 
when healing at six months is considered. Differences 
in side effect profiles should be taken into account 
when choosing treatments. Table 8 provides an outline 
of key comorbidities that clinicians may wish to con-
sider when choosing between prednisolone and ciclo-
sporin for individual patients.
These results provide robust evidence to inform shared 
treatment decision making between clinicians and 
patients, including information on duration of treatment, 
response rates, adverse effect profiles, and likelihood of 
table 6 | self reported pain during first six weeks of treatment, and health related quality of life at final visit
secondary outcomes
no in group, mean (sD) Mean difference (ciclosporin−prednisolone), 
adjusted mean difference* (95% Ci), P valueCiclosporin group Prednisolone group
Pain scores (range 0-4):
 Week 1 n=47, 1.98 (1.0) n=38, 1.84 (1.2)
 Week 2 n=46, 1.74 (1.1) n=37, 1.69 (1.3)
 Week 3 n=46, 1.59 (1.0) n=36, 1.48 (1.2)
 Week 4 n=45, 1.34 (1.2) n=35, 1.50 (1.2)
 Week 5 n=46, 1.22 (1.1) n=34, 1.49 (1.3)
 Week 6 n=45, 1.10 (1.0) n=32, 1.49 (1.3)
 Weeks 1-6: AUC (0-20) n=45, 7.5 (4.8) n=32, 7.9 (5.6) −0.40 −0.48 (−2.82 to 1.87), 0.69
DLQI (range 0-30, high score=worse):
 Baseline n=58, 10.3 (7.3) n=53, 13.2 (9.0)
−1.5, −0.45 (−3.46 to 2.56), 0.77
 Final visit n=38, 4.8 (6.8) n=28, 6.3 (7.6)
EQ-5D-3L (range-0.594-1.000, (low scores=worse):
 Baseline n=56, 0.51 (0.35) n=52, 0.44 (0.38)
0.13, 0.13 (−0.02 to 0.28), 0.095
 Final visit n=42, 0.76 (0.30) n=27, 0.63 (0.41)
EQ VAS (range 0-100, low scores=worse):
 Baseline n=57, 62.6 (22.2) n=53, 61.4 (21.5)
2.6, 0.48 (−9.3 to 10.3), 0.92
 Final visit n=41, 73.2 (20.5) n=29, 70.6 (22.3)
AUC=area under the curve; DLQI=dermatology life quality index; EQ-5D-3L=European quality of life-5 dimensions, three levels; EQ VAS=European quality of life visual analogue scale.
*Adjusted for baseline values and stratification variables (lesion size and presence of underlying disease).
table 7 | specific adverse reactions occurring in 3% or more of participants in either 
treatment group
upper and lower level classifications
no (%) in ciclosporin 
group (n=59)
no (%) in prednisolone 
group (n=53)
Blood and the lymphatic system disorders:
 Anaemia 2 (3) 0 (0)
 Leucocytosis 0 (0) 5 (9)
Endocrine disorders:
 Diabetes 0 (0) 3 (6)
Metabolism and nutrition disorders:
 Hyperglycaemia 0 (0) 5 (9)
Nervous system disorders:
 Tremor 5 (8) 2 (4)
 Headache 5 (8) 0 (0)
 Paraesthesia 2 (3) 0 (0)
 Euphoria 0 (0) 3 (6)
 Depression 1 (2) 2 (4)
Gastrointestinal disorders:
 Nausea 12 (20) 1 (2)
 Vomiting 4 (7) 0 (0)
 Diarrhoea 2 (3) 0 (0)
 Candidiasis 1 (2) 2 (4)
Cardiovascular disorders:
 Hypertension 10 (17) 4 (7)
 Oedema 0 (0) 2 (4)
Hepatobiliary disorders:
 Hepatic dysfunction 2 (3) 1 (2)
Skin and subcutaneous tissue disorders:
 Hypertrichosis 2 (3) 0 (0)
Musculoskeletal, connective tissue and bone 
disorders:
 Muscle cramps 2 (3) 0 (0)
 Myalgia 2 (3) 1 (2)
 Arthralgia 2 (3) 0 (0)
Renal and urinary disorders:
 Renal dysfunction 18 (30) 1 (2)
General disorders:
 Serious infection*: 0 (0) 6 (11)
 Other infection 4 (7) 5 (9)
 Fatigue 2 (3) 4 (7)
 Weight increase 1 (2) 4 (7)
One suspected unexpected serious adverse reaction (a ruptured abdominal aortic aneurysm) was reported 
during the trial.
*Requiring hospital admission or parenteral antibiotics.
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recurrence. However, our results suggest that better treat-
ments for pyoderma gangrenosum are urgently needed.
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Supplementary appendix: members of STOP GAP trial 
team
Supplementary figure: measurement of pyoderma 
 gangrenosum ulcer using image analysis software
table 8 | authors’ suggestions on when to consider prednisolone versus ciclosporin for 
patients with pyoderma gangrenosum based on pre-existing comorbidities
Comorbidities Favours prednisolone Favours ciclosporin
Obesity (>100 kg) Some concerns Yes
Diabetes Strong reason for not using Yes
Hypertension Some concerns Strong reason for not using
Renal insufficiency Yes Strong reason for not using
Osteoporosis Strong reason for not using Yes
Peptic ulceration Strong reason for not using Yes
Malignancy Yes Some concerns
History of mental illness Some concerns Yes
